| Identification | Back Directory | [Name]
3-Pyridinecarboximidoyl chloride, N-[2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide | [CAS]
289893-23-8 | [Synonyms]
Anti-neurodegeneration agent 1 Anti neurodegeneration agent 1,Antineurodegeneration agent 1 3-Pyridinecarboximidoyl chloride, N-[2-hydroxy-3-(1-piperidinyl)propoxy]-, 1-oxide | [Molecular Formula]
C14H20ClN3O3 | [MDL Number]
MFCD18254098 | [MOL File]
289893-23-8.mol | [Molecular Weight]
313.78 |
| Chemical Properties | Back Directory | [Boiling point ]
539.2±60.0 °C(Predicted) | [density ]
1.32±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
14.03±0.20(Predicted) |
| Hazard Information | Back Directory | [Uses]
Anti-neurodegeneration agent 1 a neurodegeneration-targeting compound extracted from patent WO2008039514A1, Compound I. | [in vivo]
In Anti-neurodegeneration agent 1 (Compound I)-treated mSODl(G93A) mice, Western blot analysis reveals an observable 'band shift' of HSF-I, indicative of a stress-induced activation of HSF-I by hyper-phosphorylation. Immunostaining reveals that, at 120 days of age, expression of Hsp70 and Hsp90 is increased in the lumbar spinal cords of both untreated and Anti-neurodegeneration agent 1- treated SOD1(G93A) mice, although there is a clear increase in the intensity of Hsp70 and Hsp90 immunoreactivity in motor neurons of Anti-neurodegeneration agent 1-treated mSODl(G93A) mice. Anti-neurodegeneration agent I- treated mice live an average of 153 days (±2.6 SEM, n=7). This represents a significant increase in lifespan of over 22% (p=<0.001). The effect of beginning Anti-neurodegeneration agent 1 treatment at the time of disease onset is also tested by starting treatment at 70 days of age, when the first signs of locomotor defects are observed. Anti-neurodegeneration agent 1 treatment from 70 days of age extended the mean lifespan of mSODl(G93A) mice by 23 days, from 125 days (±1.8 SEM, n=18) in the untreated group to 148 days (±1.5 SEM, n=5) in the treated group. This represents an increase in lifespan of 18% (p=<0.001)[1] | [storage]
Store at -20°C | [References]
[1] BARBER, Jack R. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH NEURODEGENERATION. WO2008039514A1. |
|
|